Last quarter (Q ), Corbus Pharmaceuticals's total revenue was $0.00, a decrease of -100.00% from the same quarter last year. In Q, Corbus Pharmaceuticals's net income was $-8.78M. See Corbus Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18	Dec 17
Total Revenue	-	$ 881.71K	$ 3.94M	$ 36.14M	$ 4.82M	$ 2.44M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 34.04M	$ 56.87M	$ 126.75M	$ 113.25M	$ 61.57M	$ 35.00M
Operating Income	$ -34.04M	$ -55.99M	$ -122.81M	$ -77.10M	$ -56.75M	$ -32.56M
Net Non Operating Interest Income Expense	$ -1.88M	$ -1.83M	$ -1.03M	$ 1.23M	$ 982.78K	$ 183.11K
Other Income Expense	$ -5.81M	$ 12.18M	$ 12.57M	$ 4.42M	$ 92.79K	$ -41.91K
Pretax Income	$ -41.73M	$ -45.64M	$ -111.27M	$ -71.45M	$ -55.67M	$ -32.42M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -41.73M	$ -45.64M	$ -111.27M	$ -71.45M	$ -55.67M	$ -32.42M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 34.04M	$ 56.87M	$ 126.75M	$ 113.25M	$ 61.57M	$ 35.00M
Net Income From Continuing And Discontinued Operation	$ -41.73M	$ -45.64M	$ -111.27M	$ -71.45M	$ -55.67M	$ -32.42M
Normalized Income	$ -36.13M	$ -45.92M	$ -110.57M	$ -71.30M	$ -55.76M	$ -32.38M
Interest Expense	-	-	-	-	-	-
EBIT	$ -34.04M	$ -55.99M	$ -122.81M	$ -77.10M	$ -56.75M	$ -32.56M
EBITDA	$ -32.55M	$ -54.35M	$ -121.12M	$ -75.87M	$ -56.25M	$ -32.31M

Currency in USD

Corbus Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing